<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group>
<journal-title>PLoS ONE</journal-title></journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, USA</publisher-loc></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">PONE-D-14-09359</article-id>
<article-id pub-id-type="doi">10.1371/journal.pone.0099763</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine and health sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Basic cancer research</subject><subject>Cancer treatment</subject></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>Prognostic and Clinicopathological Significance of Downregulated E-Cadherin Expression in Patients with Non-Small Cell Lung Cancer (NSCLC): A Meta-Analysis</article-title>
<alt-title alt-title-type="running-head">Prognostic Role of E-Cadherin in NSCLC</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes" xlink:type="simple"><name name-style="western"><surname>Yang</surname><given-names>Yan-Long</given-names></name><xref ref-type="aff" rid="aff1"/></contrib>
<contrib contrib-type="author" equal-contrib="yes" xlink:type="simple"><name name-style="western"><surname>Chen</surname><given-names>Ming-Wu</given-names></name><xref ref-type="aff" rid="aff1"/></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Xian</surname><given-names>Lei</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib>
</contrib-group>
<aff id="aff1"><addr-line>Department of Cardiothoracic Surgery, the First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple"><name name-style="western"><surname>Navarro</surname><given-names>Alfons</given-names></name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/></contrib>
</contrib-group>
<aff id="edit1"><addr-line>University of Barcelona, Spain</addr-line></aff>
<author-notes>
<corresp id="cor1">* E-mail: <email xlink:type="simple">xianlei59@163.com</email></corresp>
<fn fn-type="conflict"><p>The authors have declared that no competing interests exist.</p></fn>
<fn fn-type="con"><p>Conceived and designed the experiments: YLY MWC LX. Performed the experiments: YLY MWC. Analyzed the data: YLY MWC. Contributed reagents/materials/analysis tools: LX. Wrote the paper: YLY MWC LX.</p></fn>
</author-notes>
<pub-date pub-type="collection"><year>2014</year></pub-date>
<pub-date pub-type="epub"><day>30</day><month>6</month><year>2014</year></pub-date>
<volume>9</volume>
<issue>6</issue>
<elocation-id>e99763</elocation-id>
<history>
<date date-type="received"><day>28</day><month>2</month><year>2014</year></date>
<date date-type="accepted"><day>19</day><month>5</month><year>2014</year></date>
</history>
<permissions>
<copyright-year>2014</copyright-year>
<copyright-holder>Yang et al</copyright-holder><license xlink:type="simple"><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions>
<abstract><sec>
<title>Background</title>
<p>Many studies have investigated the prognostic role of E-cadherin in patients with NSCLC; however, the result still remains inconclusive. An up-to data system review and meta-analysis was necessary to give a comprehensive evaluation of prognostic role of E-cadherin in NSCLC.</p>
</sec><sec>
<title>Methods</title>
<p>Eligible studies were searched in Pubmed, Embase and Web of Science databases. The inclusion criteria were studies that assessed the relationship between E-cadherin expression detected by immunohistochemistry (IHC) and the prognosis or clinicopathological features in patients with NSCLC. Subgroup analysis according to race, percentage of reduced/negative E-cadherin expression, histological type, and sample size were also conducted. Odds ratio (OR) or hazard ratio (HR) with 95% confidence interval (CI) were calculated to examine the risk or hazard association.</p>
</sec><sec>
<title>Results</title>
<p>A total of 29 studies including 4010 patients were qualified for analysis. The analysis suggested that downregulated E-cadherin expression was significant associated with unfavorable overall survival (OS) and disease-free survival/progression-free survival (DFS/PFS) in patients with NSCLC. Subgroup analysis by race, percentage of reduced/negative E-cadherin expression, sample size also found the significant association in OS. When only the stage I NSCLC were considered, downregulated E-cadherin expression still had an unfavorable impact on OS. Additionally, downregulated E-cadherin expression was significantly associated with differentiation grade, lymphnode metastasis, vascular invasion, and TNM stage.</p>
</sec><sec>
<title>Conclusion</title>
<p>Downregulated E-cadherin expression detected by IHC seems to correlate with tumour progression and could serve as an important prognostic factor in patients with NSCLC.</p>
</sec></abstract>
<funding-group><funding-statement>This work was supported by the Guangxi Scientific Research and Technology Development projects (grant no. 10124001A- 47). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="9"/></counts></article-meta>
</front>
<body><sec id="s1">
<title>Introduction</title>
<p>Lung cancer still remains the most common cancer and the most common cause of cancer-related death worldwide. There are 1,820,000 new cases and 1,590,000 death around the world according to the International Agency for Research on Cancer (IARC) in 2012 <xref ref-type="bibr" rid="pone.0099763-International1">[1]</xref>. About 85% lung cancers were non-small cell lung cancers <xref ref-type="bibr" rid="pone.0099763-Govindan1">[2]</xref>, and approximately two thirds of NSCLC cases were diagnosis at locally advanced (27.6%) or metastatic (38.1%) disease as the typically asymptomatic at early stages <xref ref-type="bibr" rid="pone.0099763-Morgensztern1">[3]</xref>. It is well known that pathologic TNM category, age, sex, and cell type are all important prognostic factors for the patients with NSCLC <xref ref-type="bibr" rid="pone.0099763-Chansky1">[4]</xref>. The advances in molecular biology have enabled researchers to focus on molecular or biological markers in NSCLC.</p>
<p>E-cadherin, a calcium-dependent cell-cell adhesion molecule, is closely linked to the actin cytoskeleton and plays a key role in the maintenance of tissue integrity by the formation of adherens junctions <xref ref-type="bibr" rid="pone.0099763-Paredes1">[5]</xref>. Loss or dysfunction of E-cadherin is associated with an invasive phenotype in numerous cancers <xref ref-type="bibr" rid="pone.0099763-Birchmeier1">[6]</xref>. This evidence indicated that E-cadherin may play an important role in the development and progression of NSCLC and might associate with poor prognosis in patients with NSCLC. Recently, many studies have explored the prognostic role and clinicopathological outcomes in patients with NSCLC, but the results remains controversial. Some studies showed that patients with reduced E-cadherin expression may associated with progression and poor survival; other studies could not confirm this. Due to the limited sample size and static power in individual study, a meta-analysis is necessary to comprehensively evaluate the prognostic and clinicopathological significance of E-cadherin expression in patients with NSCLC.</p>
</sec><sec id="s2" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="s2a">
<title>Literature search</title>
<p>A comprehensive literature search was conducted in the databases of PubMed, EMBASE and Web of Science. The last search time was Feb 28, 2014. The following terms and combinations were used to identify studies: “E-cadherin”, “CDH1”, “lung cancer”, “lung neoplasm” and “prognosis”. Furthermore, references of retrieved articles and reviews were manually screened for additional studies.</p>
</sec><sec id="s2b">
<title>Inclusion and exclusion criteria</title>
<p>The inclusion criteria were applied to identify the eligible studies: (1) human-based investigations; (2) pathologically confirmed non-small cell lung cancer; (3) articles with full texts published in English; (4) to detect E-cadherin expression in the primary tumor tissues by immunohistochemistry (IHC) assay; (5) to evaluate the correlation between E-cadherin expression and OS, DFS/PFS, or clinicopathological parameters; (6) to provided sufficient information to estimate hazard ratio (HR) or odds ratio (OR) and their 95% confidence intervals (CIs). The exclusion criteria were as the follows: (1) studies published in non-English; (2) cell line and animal studies, case reports, letters, reviews or meta-analysis; (3) studies in which necessary data were not provided; (4) for overlapped studies, the studies with low quality were excluded.</p>
</sec><sec id="s2c">
<title>Data extraction</title>
<p>Two investigators (YL Yang and MW Chen) independently reviewed the eligible studies and extracted the following data: surname of the first author, publication year, country, ethnicity, sample size, disease stage, histology type, assay method, cut off value, distribution of reduced/negative E-cadherin expression and the outcomes. All data were then examined by two investigators independently (YL Yang and MW Chen). Disagreements were resolved by discussion among all authors.</p>
</sec><sec id="s2d">
<title>Quality Assessment</title>
<p>The quality of the methodology of the included studies was assessed by the Newcastle-Ottawa scale (NOS) recommended by the Cochrane Non-Randomized Studies Methods Working Group <xref ref-type="bibr" rid="pone.0099763-Wells1">[7]</xref>. Studies with five or more stars were defined as high quality studies. Quality assessment was performed by two investigators (YL Yang and L Xian) independently. Disagreements were resolved by discussion.</p>
</sec><sec id="s2e">
<title>Statistical Analysis</title>
<p>The impact of E-cadherin expression on survival (OS, DFS/PFS) was measured by the combined HRs and their 95% CIs extracted from each eligible study. The HR and its 95% CI in each eligible study was directly extracted from report, or indirectly estimated by methods described by Tierney <xref ref-type="bibr" rid="pone.0099763-Tierney1">[8]</xref>. The combined HRs was estimated graphically by Forest plots. For the relationship between E-cadherin expression and clinicopathological parameters, odds ratios (ORs) and their 95% CIs were combined to estimate the effective value. The overall HR/OR and its 95% CI overlap 1 was considered statistically significant and indicated a worse effect for the group with reduced/negative E-cadherin expression. Heterogeneity between studies was detected by the Q test and the I<sup>2</sup> metric (no heterogeneity: I<sup>2</sup> = 0%–25%; moderate heterogeneity: 25%–50%; large heterogeneity: 50%–75%; and extreme heterogeneity: 75%–100%) <xref ref-type="bibr" rid="pone.0099763-Higgins1">[9]</xref>. If P≥0.10 in the Q test or I<sup>2</sup>&lt;50%, the fixed-effect model (the Mantel Haenszel method) <xref ref-type="bibr" rid="pone.0099763-Mantel1">[10]</xref> was used. Otherwise, random effect model <xref ref-type="bibr" rid="pone.0099763-DerSimonian1">[11]</xref> analysis was conducted. Subgroup analysis by different analytical methods (race, percentage of reduced E-cadherin, histological type, HR estimate, and sample size) was performed in the analysis of OS. In addition, publication bias was assessed by the method reported by Begg and Egger <xref ref-type="bibr" rid="pone.0099763-Begg1">[12]</xref>, <xref ref-type="bibr" rid="pone.0099763-Egger1">[13]</xref>. All P values were two-tailed and the P value&lt;0.05 was considered statistically significant. Most of the statistical analyses in this study were conducted by the STATA software (version 11.2; StataCorp, College Station, Texas USA).</p>
</sec></sec><sec id="s3">
<title>Results</title>
<sec id="s3a">
<title>Eligible Studies</title>
<p>The present work followed the guidelines for systematic reviews and meta-analyses (PRISMA) (<xref ref-type="supplementary-material" rid="pone.0099763.s003">Checklist S1</xref>). 423 articles were identified from three databases. After reviewing the titles and abstracts, 379 articles were excluded because they obviously did not meet our selection criteria. The remaining 46 articles were further checked by screening the full texts. 17 studies were excluded for the following reasons: not an IHC method (n = 3), insufficient data (n = 5), without outcome of interest (n = 6), data overlapping (n = 3). Finally, a total of 29 studies <xref ref-type="bibr" rid="pone.0099763-Kase1">[14]</xref>–<xref ref-type="bibr" rid="pone.0099763-Zhao2">[41]</xref> including 4010 patients were qualified for our analysis. The process of article selection is summarized in <xref ref-type="fig" rid="pone-0099763-g001">Figure 1</xref>. All 29 studies were assessed by the NOS quality scale and all eligible studies scored highly (with five stars or more). The quality score of the eligible studies can be found in <xref ref-type="supplementary-material" rid="pone.0099763.s002">Table S1</xref>.</p>
<fig id="pone-0099763-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0099763.g001</object-id><label>Figure 1</label><caption>
<title>Flow diagram of studies selection procedure.</title>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0099763.g001" position="float" xlink:type="simple"/></fig>
<p>The main characteristics of qualified studies are listed in <xref ref-type="table" rid="pone-0099763-t001">Table 1</xref>. Five studies only investigated the relationship between E-cadherin expression and clinicopathological parameters <xref ref-type="bibr" rid="pone.0099763-Lim1">[37]</xref>–<xref ref-type="bibr" rid="pone.0099763-Zhao2">[41]</xref>. 22 studies investigated the impact of E-cadherin expression on overall survival (OS) <xref ref-type="bibr" rid="pone.0099763-Kase1">[14]</xref>–<xref ref-type="bibr" rid="pone.0099763-AlSaad1">[21]</xref>, <xref ref-type="bibr" rid="pone.0099763-Zhu1">[23]</xref>, <xref ref-type="bibr" rid="pone.0099763-Yamashita1">[25]</xref>–<xref ref-type="bibr" rid="pone.0099763-Yu1">[29]</xref>, <xref ref-type="bibr" rid="pone.0099763-Shiwu1">[31]</xref>–<xref ref-type="bibr" rid="pone.0099763-Zhao1">[36]</xref>, and most of them assessed the clinicopathological parameters at the same time <xref ref-type="bibr" rid="pone.0099763-Kase1">[14]</xref>–<xref ref-type="bibr" rid="pone.0099763-Tamura1">[20]</xref>, <xref ref-type="bibr" rid="pone.0099763-Yamashita1">[25]</xref>, <xref ref-type="bibr" rid="pone.0099763-Yu1">[29]</xref>, <xref ref-type="bibr" rid="pone.0099763-Shiwu1">[31]</xref>, <xref ref-type="bibr" rid="pone.0099763-Kim1">[33]</xref>, <xref ref-type="bibr" rid="pone.0099763-Zhang2">[35]</xref>. Among these 22 studies, 17 studies evaluated patients in Asian <xref ref-type="bibr" rid="pone.0099763-Kase1">[14]</xref>–<xref ref-type="bibr" rid="pone.0099763-Hirata1">[17]</xref>, <xref ref-type="bibr" rid="pone.0099763-Huang1">[19]</xref>, <xref ref-type="bibr" rid="pone.0099763-Tamura1">[20]</xref>, <xref ref-type="bibr" rid="pone.0099763-Zhu1">[23]</xref>, <xref ref-type="bibr" rid="pone.0099763-Yamashita1">[25]</xref>, <xref ref-type="bibr" rid="pone.0099763-Lin1">[26]</xref>, <xref ref-type="bibr" rid="pone.0099763-Yu1">[29]</xref>, <xref ref-type="bibr" rid="pone.0099763-Shiwu1">[31]</xref>–<xref ref-type="bibr" rid="pone.0099763-Zhao1">[36]</xref>, five studies evaluated patients in Caucasian <xref ref-type="bibr" rid="pone.0099763-Deeb1">[18]</xref>, <xref ref-type="bibr" rid="pone.0099763-AlSaad1">[21]</xref>, <xref ref-type="bibr" rid="pone.0099763-Sterlacci1">[27]</xref>, <xref ref-type="bibr" rid="pone.0099763-Ucvet1">[28]</xref>, <xref ref-type="bibr" rid="pone.0099763-Richardson1">[30]</xref>. The percentage of reduced E-cadherin expression was more than 50% in 12 studies <xref ref-type="bibr" rid="pone.0099763-Kimura1">[15]</xref>, <xref ref-type="bibr" rid="pone.0099763-Huang1">[19]</xref>, <xref ref-type="bibr" rid="pone.0099763-Tamura1">[20]</xref>, <xref ref-type="bibr" rid="pone.0099763-Lin1">[26]</xref>–<xref ref-type="bibr" rid="pone.0099763-Richardson1">[30]</xref>, <xref ref-type="bibr" rid="pone.0099763-Feng1">[32]</xref>, <xref ref-type="bibr" rid="pone.0099763-Zhao1">[36]</xref>, while 10 studies showed percentage of reduced E-cadherin expression was less than 50% <xref ref-type="bibr" rid="pone.0099763-Kase1">[14]</xref>, <xref ref-type="bibr" rid="pone.0099763-Lee1">[16]</xref>–<xref ref-type="bibr" rid="pone.0099763-Deeb1">[18]</xref>, <xref ref-type="bibr" rid="pone.0099763-AlSaad1">[21]</xref>, <xref ref-type="bibr" rid="pone.0099763-Zhu1">[23]</xref>, <xref ref-type="bibr" rid="pone.0099763-Yamashita1">[25]</xref>, <xref ref-type="bibr" rid="pone.0099763-Kim1">[33]</xref>–<xref ref-type="bibr" rid="pone.0099763-Zhang2">[35]</xref>. 11 studies investigated mostly (&gt;50%) with adenocarcinoma (AD) <xref ref-type="bibr" rid="pone.0099763-Kimura1">[15]</xref>, <xref ref-type="bibr" rid="pone.0099763-Hirata1">[17]</xref>–<xref ref-type="bibr" rid="pone.0099763-Tamura1">[20]</xref>, <xref ref-type="bibr" rid="pone.0099763-Yamashita1">[25]</xref>, <xref ref-type="bibr" rid="pone.0099763-Sterlacci1">[27]</xref>, <xref ref-type="bibr" rid="pone.0099763-Yu1">[29]</xref>, <xref ref-type="bibr" rid="pone.0099763-Kim1">[33]</xref>, <xref ref-type="bibr" rid="pone.0099763-Zhao1">[36]</xref>, eight studies investigated mostly (&gt;50%) with squamous cell carcinoma (SQ) <xref ref-type="bibr" rid="pone.0099763-AlSaad1">[21]</xref>, <xref ref-type="bibr" rid="pone.0099763-Ucvet1">[28]</xref>–<xref ref-type="bibr" rid="pone.0099763-Feng1">[32]</xref>, <xref ref-type="bibr" rid="pone.0099763-Zhang1">[34]</xref>, <xref ref-type="bibr" rid="pone.0099763-Zhang2">[35]</xref>. HR estimation of 13 studies was given by authors <xref ref-type="bibr" rid="pone.0099763-Deeb1">[18]</xref>, <xref ref-type="bibr" rid="pone.0099763-Tamura1">[20]</xref>, <xref ref-type="bibr" rid="pone.0099763-AlSaad1">[21]</xref>, <xref ref-type="bibr" rid="pone.0099763-Zhu1">[23]</xref>, <xref ref-type="bibr" rid="pone.0099763-Yamashita1">[25]</xref>–<xref ref-type="bibr" rid="pone.0099763-Sterlacci1">[27]</xref>, <xref ref-type="bibr" rid="pone.0099763-Richardson1">[30]</xref>–<xref ref-type="bibr" rid="pone.0099763-Feng1">[32]</xref>, <xref ref-type="bibr" rid="pone.0099763-Zhang1">[34]</xref>, while nine were calculated by survival curves <xref ref-type="bibr" rid="pone.0099763-Kase1">[14]</xref>–<xref ref-type="bibr" rid="pone.0099763-Hirata1">[17]</xref>, <xref ref-type="bibr" rid="pone.0099763-Huang1">[19]</xref>, <xref ref-type="bibr" rid="pone.0099763-Ucvet1">[28]</xref>, <xref ref-type="bibr" rid="pone.0099763-Yu1">[29]</xref>, <xref ref-type="bibr" rid="pone.0099763-Kim1">[33]</xref>, <xref ref-type="bibr" rid="pone.0099763-Zhang1">[34]</xref>, <xref ref-type="bibr" rid="pone.0099763-Zhao1">[36]</xref>. 13 studies enrolled less than 150 patients <xref ref-type="bibr" rid="pone.0099763-Kimura1">[15]</xref>, <xref ref-type="bibr" rid="pone.0099763-Deeb1">[18]</xref>, <xref ref-type="bibr" rid="pone.0099763-Tamura1">[20]</xref>, <xref ref-type="bibr" rid="pone.0099763-Zhu1">[23]</xref>, <xref ref-type="bibr" rid="pone.0099763-Lin1">[26]</xref>, <xref ref-type="bibr" rid="pone.0099763-Ucvet1">[28]</xref>–<xref ref-type="bibr" rid="pone.0099763-Feng1">[32]</xref>, <xref ref-type="bibr" rid="pone.0099763-Zhang1">[34]</xref>, <xref ref-type="bibr" rid="pone.0099763-Zhao1">[36]</xref> and nine studies included more than 150 patients <xref ref-type="bibr" rid="pone.0099763-Kase1">[14]</xref>, <xref ref-type="bibr" rid="pone.0099763-Lee1">[16]</xref>, <xref ref-type="bibr" rid="pone.0099763-Hirata1">[17]</xref>, <xref ref-type="bibr" rid="pone.0099763-Huang1">[19]</xref>, <xref ref-type="bibr" rid="pone.0099763-AlSaad1">[21]</xref>, <xref ref-type="bibr" rid="pone.0099763-Yamashita1">[25]</xref>, <xref ref-type="bibr" rid="pone.0099763-Sterlacci1">[27]</xref>, <xref ref-type="bibr" rid="pone.0099763-Kim1">[33]</xref>, <xref ref-type="bibr" rid="pone.0099763-Zhang2">[35]</xref>.</p>
<table-wrap id="pone-0099763-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0099763.t001</object-id><label>Table 1</label><caption>
<title>Main characteristics of all studies included in the meta-analysis.</title>
</caption><alternatives><graphic id="pone-0099763-t001-1" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0099763.t001" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1">Author,year</td>
<td align="left" rowspan="1" colspan="1">Race(country)</td>
<td align="left" rowspan="1" colspan="1">No. of patients(M/F)</td>
<td align="left" rowspan="1" colspan="1">Stage</td>
<td align="left" rowspan="1" colspan="1">Histology distribution</td>
<td align="left" rowspan="1" colspan="1">Antibody sorce(Dilution)</td>
<td align="left" rowspan="1" colspan="1">Cutoff value</td>
<td align="left" rowspan="1" colspan="1">Distribution of reduced E-cadherin (%)</td>
<td align="left" rowspan="1" colspan="1">Outcome</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">Kase,2000 <xref ref-type="bibr" rid="pone.0099763-Kase1">[14]</xref></td>
<td align="left" rowspan="1" colspan="1">Asian(Japan)</td>
<td align="left" rowspan="1" colspan="1">331(209/122)</td>
<td align="left" rowspan="1" colspan="1">I–IV</td>
<td align="left" rowspan="1" colspan="1">AD227,SQ104</td>
<td align="left" rowspan="1" colspan="1">Transduction(1∶2500)</td>
<td align="left" rowspan="1" colspan="1">0.7</td>
<td align="left" rowspan="1" colspan="1">42</td>
<td align="left" rowspan="1" colspan="1">OS,CP</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Kimura,2000 <xref ref-type="bibr" rid="pone.0099763-Kimura1">[15]</xref></td>
<td align="left" rowspan="1" colspan="1">Asian(Japan)</td>
<td align="left" rowspan="1" colspan="1">135(90/45)</td>
<td align="left" rowspan="1" colspan="1">I–IV</td>
<td align="left" rowspan="1" colspan="1">AD101,SQ25,LCC5,ADS4</td>
<td align="left" rowspan="1" colspan="1">DAKO(NR)</td>
<td align="left" rowspan="1" colspan="1">0.8</td>
<td align="left" rowspan="1" colspan="1">64.4</td>
<td align="left" rowspan="1" colspan="1">OS,CP</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Lee,2000 <xref ref-type="bibr" rid="pone.0099763-Lee1">[16]</xref></td>
<td align="left" rowspan="1" colspan="1">Asian(Taiwan)</td>
<td align="left" rowspan="1" colspan="1">207(142/65)</td>
<td align="left" rowspan="1" colspan="1">I–III</td>
<td align="left" rowspan="1" colspan="1">AD98,SQ74,BAC35</td>
<td align="left" rowspan="1" colspan="1">Takara(NR)</td>
<td align="left" rowspan="1" colspan="1">0.4</td>
<td align="left" rowspan="1" colspan="1">41</td>
<td align="left" rowspan="1" colspan="1">OS,CP</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Hirata,2001 <xref ref-type="bibr" rid="pone.0099763-Hirata1">[17]</xref></td>
<td align="left" rowspan="1" colspan="1">Asian(Japan)</td>
<td align="left" rowspan="1" colspan="1">249(171/78)</td>
<td align="left" rowspan="1" colspan="1">I–IIIA</td>
<td align="left" rowspan="1" colspan="1">AD148,SQ90,LCC8</td>
<td align="left" rowspan="1" colspan="1">Takara(NR)</td>
<td align="left" rowspan="1" colspan="1">0.1</td>
<td align="left" rowspan="1" colspan="1">47</td>
<td align="left" rowspan="1" colspan="1">OS,CP</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Deeb,2004 <xref ref-type="bibr" rid="pone.0099763-Deeb1">[18]</xref></td>
<td align="left" rowspan="1" colspan="1">Caucasian(USA)</td>
<td align="left" rowspan="1" colspan="1">118(63/55)</td>
<td align="left" rowspan="1" colspan="1">I–IIIA</td>
<td align="left" rowspan="1" colspan="1">AD81,SQ37</td>
<td align="left" rowspan="1" colspan="1">Dako(1∶50)</td>
<td align="left" rowspan="1" colspan="1">0.1</td>
<td align="left" rowspan="1" colspan="1">45</td>
<td align="left" rowspan="1" colspan="1">OS,CP</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Huang,2005 <xref ref-type="bibr" rid="pone.0099763-Huang1">[19]</xref></td>
<td align="left" rowspan="1" colspan="1">Asian(Japan)</td>
<td align="left" rowspan="1" colspan="1">173(116/57)</td>
<td align="left" rowspan="1" colspan="1">I–III</td>
<td align="left" rowspan="1" colspan="1">AD101,SQ58,LCC14</td>
<td align="left" rowspan="1" colspan="1">Vector(1∶100)</td>
<td align="left" rowspan="1" colspan="1">0.5</td>
<td align="left" rowspan="1" colspan="1">57</td>
<td align="left" rowspan="1" colspan="1">OS,CP</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Tamura,2005 <xref ref-type="bibr" rid="pone.0099763-Tamura1">[20]</xref></td>
<td align="left" rowspan="1" colspan="1">Asian(Japan)</td>
<td align="left" rowspan="1" colspan="1">131(97/34)</td>
<td align="left" rowspan="1" colspan="1">I–IIIA</td>
<td align="left" rowspan="1" colspan="1">AD81,SQ50</td>
<td align="left" rowspan="1" colspan="1">Takara(1∶200)</td>
<td align="left" rowspan="1" colspan="1">0.75</td>
<td align="left" rowspan="1" colspan="1">54</td>
<td align="left" rowspan="1" colspan="1">OS,CP</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Al-Saad,2008 <xref ref-type="bibr" rid="pone.0099763-AlSaad1">[21]</xref></td>
<td align="left" rowspan="1" colspan="1">Caucasian(Norway)</td>
<td align="left" rowspan="1" colspan="1">335(253/82)</td>
<td align="left" rowspan="1" colspan="1">I–IIIA</td>
<td align="left" rowspan="1" colspan="1">AD95,SQ191,LCC31,BAC18</td>
<td align="left" rowspan="1" colspan="1">Rocklin(NR)</td>
<td align="left" rowspan="1" colspan="1">Score = 2</td>
<td align="left" rowspan="1" colspan="1">40</td>
<td align="left" rowspan="1" colspan="1">OS</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Cho,2008 <xref ref-type="bibr" rid="pone.0099763-Cho1">[22]</xref></td>
<td align="left" rowspan="1" colspan="1">Asian(Korea)</td>
<td align="left" rowspan="1" colspan="1">55(31/24)</td>
<td align="left" rowspan="1" colspan="1">I</td>
<td align="left" rowspan="1" colspan="1">AD55</td>
<td align="left" rowspan="1" colspan="1">Zymed(NR)</td>
<td align="left" rowspan="1" colspan="1">0.25</td>
<td align="left" rowspan="1" colspan="1">13</td>
<td align="left" rowspan="1" colspan="1">DFS</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Zhu,2009 <xref ref-type="bibr" rid="pone.0099763-Zhu1">[23]</xref></td>
<td align="left" rowspan="1" colspan="1">Asian(China)</td>
<td align="left" rowspan="1" colspan="1">148(114/34)</td>
<td align="left" rowspan="1" colspan="1">IB</td>
<td align="left" rowspan="1" colspan="1">AD42,SQ58,LCC2,BAC27,other19</td>
<td align="left" rowspan="1" colspan="1">Fuzhou maxim(NR)</td>
<td align="left" rowspan="1" colspan="1">ROC</td>
<td align="left" rowspan="1" colspan="1">12.8</td>
<td align="left" rowspan="1" colspan="1">OS</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Ono,2010 <xref ref-type="bibr" rid="pone.0099763-Ono1">[24]</xref></td>
<td align="left" rowspan="1" colspan="1">Asian(Japan)</td>
<td align="left" rowspan="1" colspan="1">107(71/36)</td>
<td align="left" rowspan="1" colspan="1">I</td>
<td align="left" rowspan="1" colspan="1">AD74,other33</td>
<td align="left" rowspan="1" colspan="1">BD(1∶200)</td>
<td align="left" rowspan="1" colspan="1">0.7</td>
<td align="left" rowspan="1" colspan="1">17</td>
<td align="left" rowspan="1" colspan="1">DFS</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Yamashita,2010 <xref ref-type="bibr" rid="pone.0099763-Yamashita1">[25]</xref></td>
<td align="left" rowspan="1" colspan="1">Asian(Japan)</td>
<td align="left" rowspan="1" colspan="1">117(77/40)</td>
<td align="left" rowspan="1" colspan="1">I</td>
<td align="left" rowspan="1" colspan="1">AD78,SQ31,LCC6,other2</td>
<td align="left" rowspan="1" colspan="1">BD(1∶200)</td>
<td align="left" rowspan="1" colspan="1">0.7</td>
<td align="left" rowspan="1" colspan="1">40</td>
<td align="left" rowspan="1" colspan="1">OS,CP</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Lin,2010 <xref ref-type="bibr" rid="pone.0099763-Lin1">[26]</xref></td>
<td align="left" rowspan="1" colspan="1">Asian(China)</td>
<td align="left" rowspan="1" colspan="1">185(115/70)</td>
<td align="left" rowspan="1" colspan="1">I</td>
<td align="left" rowspan="1" colspan="1">SQ63,non-SQ132</td>
<td align="left" rowspan="1" colspan="1">Takara(1∶400)</td>
<td align="left" rowspan="1" colspan="1">0.5</td>
<td align="left" rowspan="1" colspan="1">51</td>
<td align="left" rowspan="1" colspan="1">OS</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Sterlacci,2010 <xref ref-type="bibr" rid="pone.0099763-Sterlacci1">[27]</xref></td>
<td align="left" rowspan="1" colspan="1">Caucasian(Austria)</td>
<td align="left" rowspan="1" colspan="1">405(292/113)</td>
<td align="left" rowspan="1" colspan="1">I–IV</td>
<td align="left" rowspan="1" colspan="1">AD207,SQ126,LCC56,other16</td>
<td align="left" rowspan="1" colspan="1">DAKO(NR)</td>
<td align="left" rowspan="1" colspan="1">0.25</td>
<td align="left" rowspan="1" colspan="1">51</td>
<td align="left" rowspan="1" colspan="1">OS</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Ucvet,2011 <xref ref-type="bibr" rid="pone.0099763-Ucvet1">[28]</xref></td>
<td align="left" rowspan="1" colspan="1">Caucasian(Turkey)</td>
<td align="left" rowspan="1" colspan="1">117(111/6)</td>
<td align="left" rowspan="1" colspan="1">I–IV</td>
<td align="left" rowspan="1" colspan="1">AD47,SQ62,LCC7,other1</td>
<td align="left" rowspan="1" colspan="1">BioGenex(1∶10)</td>
<td align="left" rowspan="1" colspan="1">0.5</td>
<td align="left" rowspan="1" colspan="1">75</td>
<td align="left" rowspan="1" colspan="1">OS</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Yu,2011 <xref ref-type="bibr" rid="pone.0099763-Yu1">[29]</xref></td>
<td align="left" rowspan="1" colspan="1">Asian(China)</td>
<td align="left" rowspan="1" colspan="1">44(22/22)</td>
<td align="left" rowspan="1" colspan="1">I–IV</td>
<td align="left" rowspan="1" colspan="1">AD44</td>
<td align="left" rowspan="1" colspan="1">Santa Cruz(1∶200)</td>
<td align="left" rowspan="1" colspan="1">0.75</td>
<td align="left" rowspan="1" colspan="1">57</td>
<td align="left" rowspan="1" colspan="1">OS,CP</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Yu,2011 <xref ref-type="bibr" rid="pone.0099763-Yu1">[29]</xref></td>
<td align="left" rowspan="1" colspan="1">Asian(China)</td>
<td align="left" rowspan="1" colspan="1">57(42/15)</td>
<td align="left" rowspan="1" colspan="1">I–IV</td>
<td align="left" rowspan="1" colspan="1">SQ57</td>
<td align="left" rowspan="1" colspan="1">Santa Cruz(1∶200)</td>
<td align="left" rowspan="1" colspan="1">0.75</td>
<td align="left" rowspan="1" colspan="1">60</td>
<td align="left" rowspan="1" colspan="1">OS,CP</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Richardson,2012 <xref ref-type="bibr" rid="pone.0099763-Richardson1">[30]</xref></td>
<td align="left" rowspan="1" colspan="1">Caucasian(USA)</td>
<td align="left" rowspan="1" colspan="1">38(NR)</td>
<td align="left" rowspan="1" colspan="1">I–IV</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">Danvers(1∶50)</td>
<td align="left" rowspan="1" colspan="1">0.1</td>
<td align="left" rowspan="1" colspan="1">68</td>
<td align="left" rowspan="1" colspan="1">PFS</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Wu,2012 <xref ref-type="bibr" rid="pone.0099763-Shiwu1">[31]</xref></td>
<td align="left" rowspan="1" colspan="1">Asian(China)</td>
<td align="left" rowspan="1" colspan="1">50(38/12)</td>
<td align="left" rowspan="1" colspan="1">I–III</td>
<td align="left" rowspan="1" colspan="1">AD14,SQ36</td>
<td align="left" rowspan="1" colspan="1">Labvision(NR)</td>
<td align="left" rowspan="1" colspan="1">Score = 1</td>
<td align="left" rowspan="1" colspan="1">52</td>
<td align="left" rowspan="1" colspan="1">OS,CP</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Feng,2012 <xref ref-type="bibr" rid="pone.0099763-Feng1">[32]</xref></td>
<td align="left" rowspan="1" colspan="1">Asian(China)</td>
<td align="left" rowspan="1" colspan="1">103(71/32)</td>
<td align="left" rowspan="1" colspan="1">I–IV</td>
<td align="left" rowspan="1" colspan="1">AD46,SQ55</td>
<td align="left" rowspan="1" colspan="1">Invitrogen(1∶200)</td>
<td align="left" rowspan="1" colspan="1">0.1</td>
<td align="left" rowspan="1" colspan="1">66</td>
<td align="left" rowspan="1" colspan="1">OS</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Kim,2013 <xref ref-type="bibr" rid="pone.0099763-Kim1">[33]</xref></td>
<td align="left" rowspan="1" colspan="1">Asian(Korea)</td>
<td align="left" rowspan="1" colspan="1">193(90/103)</td>
<td align="left" rowspan="1" colspan="1">I–III</td>
<td align="left" rowspan="1" colspan="1">AD193</td>
<td align="left" rowspan="1" colspan="1">BD(1∶200)</td>
<td align="left" rowspan="1" colspan="1">Score = 100</td>
<td align="left" rowspan="1" colspan="1">18</td>
<td align="left" rowspan="1" colspan="1">OS,CP</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Zhang X,2013 <xref ref-type="bibr" rid="pone.0099763-Zhang1">[34]</xref></td>
<td align="left" rowspan="1" colspan="1">Asian(China)</td>
<td align="left" rowspan="1" colspan="1">118(76/42)</td>
<td align="left" rowspan="1" colspan="1">I–IIIA</td>
<td align="left" rowspan="1" colspan="1">AD35,SQ74,other9</td>
<td align="left" rowspan="1" colspan="1">BD(1∶400)</td>
<td align="left" rowspan="1" colspan="1">0.66</td>
<td align="left" rowspan="1" colspan="1">48</td>
<td align="left" rowspan="1" colspan="1">OS</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Zhang H,2013 <xref ref-type="bibr" rid="pone.0099763-Zhang2">[35]</xref></td>
<td align="left" rowspan="1" colspan="1">Asian(China)</td>
<td align="left" rowspan="1" colspan="1">204(173/31)</td>
<td align="left" rowspan="1" colspan="1">I–IIIA</td>
<td align="left" rowspan="1" colspan="1">SQ</td>
<td align="left" rowspan="1" colspan="1">Invitrogen(1∶200)</td>
<td align="left" rowspan="1" colspan="1">Score = 4</td>
<td align="left" rowspan="1" colspan="1">49.5</td>
<td align="left" rowspan="1" colspan="1">OS,CP</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Zhao C,2013 <xref ref-type="bibr" rid="pone.0099763-Zhao1">[36]</xref></td>
<td align="left" rowspan="1" colspan="1">Asian(China)</td>
<td align="left" rowspan="1" colspan="1">119(93/26)</td>
<td align="left" rowspan="1" colspan="1">I–IV</td>
<td align="left" rowspan="1" colspan="1">AD61,SQ58</td>
<td align="left" rowspan="1" colspan="1">Santa Cruz(1∶100)</td>
<td align="left" rowspan="1" colspan="1">0.1</td>
<td align="left" rowspan="1" colspan="1">53.9</td>
<td align="left" rowspan="1" colspan="1">OS</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Lim,2000 <xref ref-type="bibr" rid="pone.0099763-Lim1">[37]</xref></td>
<td align="left" rowspan="1" colspan="1">Asian(Korea)</td>
<td align="left" rowspan="1" colspan="1">175(162/13)</td>
<td align="left" rowspan="1" colspan="1">I–IV</td>
<td align="left" rowspan="1" colspan="1">AD20.6,SQ79.4</td>
<td align="left" rowspan="1" colspan="1">DAKO(NR)</td>
<td align="left" rowspan="1" colspan="1">0.5</td>
<td align="left" rowspan="1" colspan="1">46.8</td>
<td align="left" rowspan="1" colspan="1">CP</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Pagaki,2010 <xref ref-type="bibr" rid="pone.0099763-Pagaki1">[38]</xref></td>
<td align="left" rowspan="1" colspan="1">Caucasian(Greece)</td>
<td align="left" rowspan="1" colspan="1">70</td>
<td align="left" rowspan="1" colspan="1">I–IV</td>
<td align="left" rowspan="1" colspan="1">AD23.9,SQ67.1</td>
<td align="left" rowspan="1" colspan="1">Menarini(NR)</td>
<td align="left" rowspan="1" colspan="1">0.1</td>
<td align="left" rowspan="1" colspan="1">55.7</td>
<td align="left" rowspan="1" colspan="1">CP</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Jin,2012 <xref ref-type="bibr" rid="pone.0099763-Jin1">[39]</xref></td>
<td align="left" rowspan="1" colspan="1">Asian(China)</td>
<td align="left" rowspan="1" colspan="1">46(28/18)</td>
<td align="left" rowspan="1" colspan="1">I–III</td>
<td align="left" rowspan="1" colspan="1">AD43.5,SQ37.0</td>
<td align="left" rowspan="1" colspan="1">Maixin(1∶50)</td>
<td align="left" rowspan="1" colspan="1">0.25</td>
<td align="left" rowspan="1" colspan="1">60.9</td>
<td align="left" rowspan="1" colspan="1">CP</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Shi,2013 <xref ref-type="bibr" rid="pone.0099763-Shi1">[40]</xref></td>
<td align="left" rowspan="1" colspan="1">Asian(China)</td>
<td align="left" rowspan="1" colspan="1">95(56/39)</td>
<td align="left" rowspan="1" colspan="1">I–IV</td>
<td align="left" rowspan="1" colspan="1">AD95</td>
<td align="left" rowspan="1" colspan="1">Zymed(1∶200)</td>
<td align="left" rowspan="1" colspan="1">Score = 4</td>
<td align="left" rowspan="1" colspan="1">56.8</td>
<td align="left" rowspan="1" colspan="1">CP</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Zhao J,2013 <xref ref-type="bibr" rid="pone.0099763-Zhao2">[41]</xref></td>
<td align="left" rowspan="1" colspan="1">Asian(China)</td>
<td align="left" rowspan="1" colspan="1">50(39/11)</td>
<td align="left" rowspan="1" colspan="1">I–IV</td>
<td align="left" rowspan="1" colspan="1">AD25,SQ19,LCC6</td>
<td align="left" rowspan="1" colspan="1">Zymed(NR)</td>
<td align="left" rowspan="1" colspan="1">0.6</td>
<td align="left" rowspan="1" colspan="1">44</td>
<td align="left" rowspan="1" colspan="1">CP</td>
</tr>
</tbody>
</table>
</alternatives><table-wrap-foot><fn id="nt101"><label/><p><bold>M</bold>: male; <bold>F</bold>: female; <bold>AD</bold>: adenocarcinoma; <bold>SQ</bold>: squamous cell carcinoma; <bold>OS</bold>: overall survival; <bold>DFS</bold>: disease-free survival; <bold>PFS</bold>: progression-free survival; <bold>CP:</bold> Clinicopathological parameters; <bold>NR</bold>: not reported.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3b">
<title>E-cadherin expression and OS in patients with NSCLC</title>
<p>22 studies including 3575 patients were eligible for the final analysis <xref ref-type="bibr" rid="pone.0099763-Kase1">[14]</xref>–<xref ref-type="bibr" rid="pone.0099763-AlSaad1">[21]</xref>, <xref ref-type="bibr" rid="pone.0099763-Zhu1">[23]</xref>, <xref ref-type="bibr" rid="pone.0099763-Yamashita1">[25]</xref>–<xref ref-type="bibr" rid="pone.0099763-Zhao1">[36]</xref>. Our analysis suggested that reduced E-cadherin expression was significantly associated with poor OS when compared to preserved E-cadherin expression (HR = 1.59, 95% CI = 1.39–1.80, <italic>p</italic>&lt;0.001), with moderate heterogeneity between studies (I<sup>2</sup> = 34.8%, P = 0.056) (<xref ref-type="fig" rid="pone-0099763-g002">Figure 2</xref>).</p>
<fig id="pone-0099763-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0099763.g002</object-id><label>Figure 2</label><caption>
<title>Forrest plot of hazard ratio (HR) for the association of E-cadherin expression with overall survival (OS) in patients with NSCLC.</title>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0099763.g002" position="float" xlink:type="simple"/></fig>
<p>Further subgroup analysis by race suggested that both Asian and Caucasian patients with reduced E-cadherin had a significant impact on OS (Asian: HR = 1.67, 95% CI = 1.42–1.96, <italic>p</italic>&lt;0.001, I<sup>2</sup> = 41.5%, P = 0.038; Caucasian: HR = 1.37, 95% CI = 1.12–1.66, <italic>p</italic> = 0.002, I<sup>2</sup> = 0.0%, P = 0.592). When grouped according to the percentage of reduced E-cadherin expression, both studies with reduced E-cadherin &gt;50% and ≤50% suggested the significant results (reduced E-cadherin ≤50%: HR = 1.55, 95% CI = 1.30–1.86, <italic>p</italic>&lt;0.001, I<sup>2</sup> = 45.7%, P = 0.056; reduced E-cadherin &gt;50%: HR = 1.58, 95% CI = 1.36–1.85, <italic>p</italic>&lt;0.001, I<sup>2</sup> = 28.9%, P = 0.162). We then focused on the predominant histological type in each study. When we limited the analysis to the studies investigating mostly (&gt;50%) with AD, the pooled HR was 1.65 (95% CI = 1.44–1.89, <italic>p</italic>&lt;0.001, I<sup>2</sup> = 33.2%, P = 0.133). When we limited the analysis to the studies investigating mostly (&gt;50%) with SQ, the pooled HR was 1.52 (95% CI = 1.29–1.80, <italic>p</italic>&lt;0.001, I<sup>2</sup> = 29.6%, P = 0.192). When the HRs derived from direct reports from 13 evaluable studies were aggregated, the combined HR was 1.63 (95% CI = 1.43–1.86, <italic>p</italic>&lt;0.001), with moderate heterogeneity between studies (I<sup>2</sup> = 34.3%, P = 0.108); when the survival data calculated indirectly from Kaplan-Meier based survival curve in nine studies were pooled, the combined HR was 1.45 (95% CI = 1.25–1.67) (<italic>p</italic>&lt;0.001), with moderate heterogeneity between studies (I<sup>2</sup> = 35.6%, P = 0.133). Subgroup analysis on sample size did not alter the significant prognostic impact of downregulated E-cadherin expression (<xref ref-type="table" rid="pone-0099763-t002">Table 2</xref>).</p>
<table-wrap id="pone-0099763-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0099763.t002</object-id><label>Table 2</label><caption>
<title>Main meta-analysis results of E-cadherin expression in patients with NSCLC.</title>
</caption><alternatives><graphic id="pone-0099763-t002-2" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0099763.t002" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1">Analysis</td>
<td align="left" rowspan="1" colspan="1">No.of studies(No. of patients)</td>
<td align="left" rowspan="1" colspan="1">HR(95%CI)</td>
<td align="left" rowspan="1" colspan="1"><italic>P</italic></td>
<td align="left" rowspan="1" colspan="1">Model</td>
<td colspan="2" align="left" rowspan="1">Heterogeneity</td>
<td colspan="2" align="left" rowspan="1">Publication bias</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">I<sup>2</sup> (%)</td>
<td align="left" rowspan="1" colspan="1">P<sub>het</sub></td>
<td align="left" rowspan="1" colspan="1">Begg's <italic>p</italic></td>
<td align="left" rowspan="1" colspan="1">Egger's <italic>p</italic></td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>OS</bold></td>
<td align="left" rowspan="1" colspan="1">22(3574)</td>
<td align="left" rowspan="1" colspan="1">1.59(1.39,1.80)</td>
<td align="left" rowspan="1" colspan="1">&lt;0.001</td>
<td align="left" rowspan="1" colspan="1">R</td>
<td align="left" rowspan="1" colspan="1">34.8</td>
<td align="left" rowspan="1" colspan="1">0.056</td>
<td align="left" rowspan="1" colspan="1">0.159</td>
<td align="left" rowspan="1" colspan="1">0.051</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Subgroup 1: race</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Asian</td>
<td align="left" rowspan="1" colspan="1">17(2561)</td>
<td align="left" rowspan="1" colspan="1">1.67(1.42,1.96)</td>
<td align="left" rowspan="1" colspan="1">&lt;0.001</td>
<td align="left" rowspan="1" colspan="1">R</td>
<td align="left" rowspan="1" colspan="1">41.5</td>
<td align="left" rowspan="1" colspan="1">0.038</td>
<td align="left" rowspan="1" colspan="1">0.266</td>
<td align="left" rowspan="1" colspan="1">0.078</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Caucasian</td>
<td align="left" rowspan="1" colspan="1">5(1013)</td>
<td align="left" rowspan="1" colspan="1">1.37(1.12,1.66)</td>
<td align="left" rowspan="1" colspan="1">0.002</td>
<td align="left" rowspan="1" colspan="1">F</td>
<td align="left" rowspan="1" colspan="1">0.0</td>
<td align="left" rowspan="1" colspan="1">0.592</td>
<td align="left" rowspan="1" colspan="1">0.462</td>
<td align="left" rowspan="1" colspan="1">0.483</td>
</tr>
<tr>
<td colspan="2" align="left" rowspan="1">Subgroup2: percentage of reduced E-cadherin</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">≤50%</td>
<td align="left" rowspan="1" colspan="1">10(2085)</td>
<td align="left" rowspan="1" colspan="1">1.55(1.30,1.86)</td>
<td align="left" rowspan="1" colspan="1">&lt;0.001</td>
<td align="left" rowspan="1" colspan="1">R</td>
<td align="left" rowspan="1" colspan="1">45.7</td>
<td align="left" rowspan="1" colspan="1">0.056</td>
<td align="left" rowspan="1" colspan="1">0.474</td>
<td align="left" rowspan="1" colspan="1">0.301</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">&gt;50%</td>
<td align="left" rowspan="1" colspan="1">12(1489)</td>
<td align="left" rowspan="1" colspan="1">1.58(1.36,1.85)</td>
<td align="left" rowspan="1" colspan="1">&lt;0.001</td>
<td align="left" rowspan="1" colspan="1">F</td>
<td align="left" rowspan="1" colspan="1">28.9</td>
<td align="left" rowspan="1" colspan="1">0.162</td>
<td align="left" rowspan="1" colspan="1">0.373</td>
<td align="left" rowspan="1" colspan="1">0.109</td>
</tr>
<tr>
<td colspan="2" align="left" rowspan="1">Subgroup3: histology type</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td colspan="2" align="left" rowspan="1">AD(&gt;50)</td>
<td align="left" rowspan="1" colspan="1">11(2083)</td>
<td align="left" rowspan="1" colspan="1">1.65(1.44,1.89)</td>
<td align="left" rowspan="1" colspan="1">&lt;0.001</td>
<td align="left" rowspan="1" colspan="1">F</td>
<td align="left" rowspan="1" colspan="1">33.2</td>
<td align="left" rowspan="1" colspan="1">0.133</td>
<td align="left" rowspan="1" colspan="1">0.436</td>
</tr>
<tr>
<td colspan="2" align="left" rowspan="1">SQ(&gt;50)</td>
<td align="left" rowspan="1" colspan="1">8(1022)</td>
<td align="left" rowspan="1" colspan="1">1.52(1.29,1.80)</td>
<td align="left" rowspan="1" colspan="1">&lt;0.001</td>
<td align="left" rowspan="1" colspan="1">F</td>
<td align="left" rowspan="1" colspan="1">29.6</td>
<td align="left" rowspan="1" colspan="1">0.192</td>
<td align="left" rowspan="1" colspan="1">0.902</td>
</tr>
<tr>
<td colspan="2" align="left" rowspan="1">Subgroup4: HR estimate</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Sur. Curve</td>
<td align="left" rowspan="1" colspan="1">9(1506)</td>
<td align="left" rowspan="1" colspan="1">1.45(1.25,1.67)</td>
<td align="left" rowspan="1" colspan="1">&lt;0.001</td>
<td align="left" rowspan="1" colspan="1">F</td>
<td align="left" rowspan="1" colspan="1">35.6</td>
<td align="left" rowspan="1" colspan="1">0.133</td>
<td align="left" rowspan="1" colspan="1">0.754</td>
<td align="left" rowspan="1" colspan="1">0.507</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">HR reported</td>
<td align="left" rowspan="1" colspan="1">13(2068)</td>
<td align="left" rowspan="1" colspan="1">1.63(1.43,1.86)</td>
<td align="left" rowspan="1" colspan="1">&lt;0.001</td>
<td align="left" rowspan="1" colspan="1">F</td>
<td align="left" rowspan="1" colspan="1">34.3</td>
<td align="left" rowspan="1" colspan="1">0.108</td>
<td align="left" rowspan="1" colspan="1">0.2</td>
<td align="left" rowspan="1" colspan="1">0.064</td>
</tr>
<tr>
<td colspan="2" align="left" rowspan="1">Subgroup5: sample size</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">&gt;150</td>
<td align="left" rowspan="1" colspan="1">9(2282)</td>
<td align="left" rowspan="1" colspan="1">1.52(1.28,1.80)</td>
<td align="left" rowspan="1" colspan="1">&lt;0.001</td>
<td align="left" rowspan="1" colspan="1">R</td>
<td align="left" rowspan="1" colspan="1">45.7</td>
<td align="left" rowspan="1" colspan="1">0.065</td>
<td align="left" rowspan="1" colspan="1">0.348</td>
<td align="left" rowspan="1" colspan="1">0.312</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">≤150</td>
<td align="left" rowspan="1" colspan="1">13(1292)</td>
<td align="left" rowspan="1" colspan="1">1.65(1.40,1.95)</td>
<td align="left" rowspan="1" colspan="1">&lt;0.001</td>
<td align="left" rowspan="1" colspan="1">F</td>
<td align="left" rowspan="1" colspan="1">27.4</td>
<td align="left" rowspan="1" colspan="1">0.168</td>
<td align="left" rowspan="1" colspan="1">0.36</td>
<td align="left" rowspan="1" colspan="1">0.136</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>OS for stage I patients</bold></td>
<td align="left" rowspan="1" colspan="1">6(717)</td>
<td align="left" rowspan="1" colspan="1">1.43(1.14,1.79)</td>
<td align="left" rowspan="1" colspan="1">0.002</td>
<td align="left" rowspan="1" colspan="1">F</td>
<td align="left" rowspan="1" colspan="1">15.5</td>
<td align="left" rowspan="1" colspan="1">0.314</td>
<td align="left" rowspan="1" colspan="1">0.26</td>
<td align="left" rowspan="1" colspan="1">0.281</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>DFS/PFS</bold></td>
<td align="left" rowspan="1" colspan="1">4(403)</td>
<td align="left" rowspan="1" colspan="1">1.58(1.21,2.05)</td>
<td align="left" rowspan="1" colspan="1">0.001</td>
<td align="left" rowspan="1" colspan="1">F</td>
<td align="left" rowspan="1" colspan="1">20.6</td>
<td align="left" rowspan="1" colspan="1">0.286</td>
<td align="left" rowspan="1" colspan="1">0.734</td>
<td align="left" rowspan="1" colspan="1">0.521</td>
</tr>
<tr>
<td colspan="2" align="left" rowspan="1"><bold>Clinicopathological parameters</bold></td>
<td align="left" rowspan="1" colspan="1"><bold>OR(95%CI)</bold></td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Histology(AD vs SQ)</td>
<td align="left" rowspan="1" colspan="1">12(1371)</td>
<td align="left" rowspan="1" colspan="1">0.95(0.65,1.39)</td>
<td align="left" rowspan="1" colspan="1">0.795</td>
<td align="left" rowspan="1" colspan="1">R</td>
<td align="left" rowspan="1" colspan="1">59.6</td>
<td align="left" rowspan="1" colspan="1">0.004</td>
<td align="left" rowspan="1" colspan="1">0.374</td>
<td align="left" rowspan="1" colspan="1">0.264</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Differentiation(M/P vs W)</td>
<td align="left" rowspan="1" colspan="1">13(1950)</td>
<td align="left" rowspan="1" colspan="1">1.71(1.15,2.53)</td>
<td align="left" rowspan="1" colspan="1">0.008</td>
<td align="left" rowspan="1" colspan="1">R</td>
<td align="left" rowspan="1" colspan="1">68.6</td>
<td align="left" rowspan="1" colspan="1">&lt;0.001</td>
<td align="left" rowspan="1" colspan="1">0.2</td>
<td align="left" rowspan="1" colspan="1">0.061</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Tumor size(T1/T2 vs T3/T4)</td>
<td align="left" rowspan="1" colspan="1">6(1152)</td>
<td align="left" rowspan="1" colspan="1">1.12(0.84,1.50)</td>
<td align="left" rowspan="1" colspan="1">0.435</td>
<td align="left" rowspan="1" colspan="1">F</td>
<td align="left" rowspan="1" colspan="1">45.7</td>
<td align="left" rowspan="1" colspan="1">0.101</td>
<td align="left" rowspan="1" colspan="1">0.707</td>
<td align="left" rowspan="1" colspan="1">0.382</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Lymphnode status (Yes vs. No)</td>
<td align="left" rowspan="1" colspan="1">10(1578)</td>
<td align="left" rowspan="1" colspan="1">2.07(1.42,3.02)</td>
<td align="left" rowspan="1" colspan="1">0.001</td>
<td align="left" rowspan="1" colspan="1">R</td>
<td align="left" rowspan="1" colspan="1">71.8</td>
<td align="left" rowspan="1" colspan="1">&lt;0.001</td>
<td align="left" rowspan="1" colspan="1">0.21</td>
<td align="left" rowspan="1" colspan="1">0.099</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Pleural invasion(Yes vs No)</td>
<td align="left" rowspan="1" colspan="1">3(366)</td>
<td align="left" rowspan="1" colspan="1">4.29(0.82,22.44)</td>
<td align="left" rowspan="1" colspan="1">0.085</td>
<td align="left" rowspan="1" colspan="1">R</td>
<td align="left" rowspan="1" colspan="1">85.8</td>
<td align="left" rowspan="1" colspan="1">0.001</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">0.901</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Vascular invasion(Yes vs No)</td>
<td align="left" rowspan="1" colspan="1">2(428)</td>
<td align="left" rowspan="1" colspan="1">2.86(1.43,5.73)</td>
<td align="left" rowspan="1" colspan="1">0.003</td>
<td align="left" rowspan="1" colspan="1">F</td>
<td align="left" rowspan="1" colspan="1">0.0</td>
<td align="left" rowspan="1" colspan="1">0.755</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">-</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Stage (III/IV vs.I/II)</td>
<td align="left" rowspan="1" colspan="1">12(1659)</td>
<td align="left" rowspan="1" colspan="1">1.87(1.27,2.76)</td>
<td align="left" rowspan="1" colspan="1">0.002</td>
<td align="left" rowspan="1" colspan="1">R</td>
<td align="left" rowspan="1" colspan="1">64.2</td>
<td align="left" rowspan="1" colspan="1">0.001</td>
<td align="left" rowspan="1" colspan="1">0.086</td>
<td align="left" rowspan="1" colspan="1">0.117</td>
</tr>
</tbody>
</table>
</alternatives><table-wrap-foot><fn id="nt102"><label/><p><bold>HR</bold>: hazard ratio; <bold>OR</bold>: odds ratio; <bold>95%CI</bold>: 95% confidence interval; <bold>F</bold>: fixed-effect model; <bold>R</bold>: random effect model; <bold>P<sub>het</sub></bold>: P for Heterogeneity; <bold>AD</bold>: adenocarcinoma; <bold>SQ</bold>: squamous cell carcinoma; <bold>OS</bold>: overall survival; <bold>DFS</bold>: disease-free survival; <bold>PFS</bold>: progression-free survival; <bold>W</bold>: well differentiation; <bold>M</bold>: moderate differentiation; <bold>P</bold>: poor differentiation.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3c">
<title>E-cadherin expression and OS in patients with stage I NSCLC</title>
<p>We separately analyzed the studies with stage I NSCLC. In these six studies with 717 patients <xref ref-type="bibr" rid="pone.0099763-Lee1">[16]</xref>, <xref ref-type="bibr" rid="pone.0099763-Hirata1">[17]</xref>, <xref ref-type="bibr" rid="pone.0099763-Huang1">[19]</xref>, <xref ref-type="bibr" rid="pone.0099763-Zhu1">[23]</xref>, <xref ref-type="bibr" rid="pone.0099763-Yamashita1">[25]</xref>, <xref ref-type="bibr" rid="pone.0099763-Lin1">[26]</xref>, the combined HR was 1.43 (95% CI = 1.14–1.79, <italic>p</italic> = 0.002), without heterogeneity between studies (I<sup>2</sup> = 15.5%, P = 0.314), indicating that reduced E-cadherin expression had significant impact on survival in patients with stage I NSCLC (<xref ref-type="fig" rid="pone-0099763-g003">Figure 3</xref>).</p>
<fig id="pone-0099763-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0099763.g003</object-id><label>Figure 3</label><caption>
<title>Forrest plot of hazard ratio (HR) for the association of E-cadherin expression with overall survival (OS) in patients with stage I NSCLC.</title>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0099763.g003" position="float" xlink:type="simple"/></fig></sec><sec id="s3d">
<title>E-cadherin expression and DFS/PFS in patients with NSCLC</title>
<p>Four studies including 403 patients were eligible for the final analysis <xref ref-type="bibr" rid="pone.0099763-Cho1">[22]</xref>, <xref ref-type="bibr" rid="pone.0099763-Ono1">[24]</xref>, <xref ref-type="bibr" rid="pone.0099763-Richardson1">[30]</xref>, <xref ref-type="bibr" rid="pone.0099763-Zhang2">[35]</xref>. Only one studies evaluated PFS <xref ref-type="bibr" rid="pone.0099763-Richardson1">[30]</xref> and the remaining studies evaluated DFS. Our analysis suggested that reduced E-cadherin expression was significant associated with worse DFS/PFS when compared to reserved E-cadherin expression (HR = 1.58, 95% CI = 1.21–2.05, <italic>p</italic> = 0.001, I<sup>2</sup> = 20.6, P = 0.286) (<xref ref-type="fig" rid="pone-0099763-g004">Figure 4</xref>).</p>
<fig id="pone-0099763-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0099763.g004</object-id><label>Figure 4</label><caption>
<title>Forrest plot of hazard ratio (HR) for the association of E-cadherin expression with disease-free survival/progression-free survival (DFS/PFS) in patients with NSCLC.</title>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0099763.g004" position="float" xlink:type="simple"/></fig></sec><sec id="s3e">
<title>E-cadherin expression and clinicopathological parameters in patients with NSCLC</title>
<p>The following clinicopathological parameters extracted from studies were collected for analysis: histological type <xref ref-type="bibr" rid="pone.0099763-Lee1">[16]</xref>, <xref ref-type="bibr" rid="pone.0099763-Hirata1">[17]</xref>, <xref ref-type="bibr" rid="pone.0099763-Huang1">[19]</xref>, <xref ref-type="bibr" rid="pone.0099763-Tamura1">[20]</xref>, <xref ref-type="bibr" rid="pone.0099763-Yu1">[29]</xref>, <xref ref-type="bibr" rid="pone.0099763-Shiwu1">[31]</xref>, <xref ref-type="bibr" rid="pone.0099763-Kim1">[33]</xref>, <xref ref-type="bibr" rid="pone.0099763-Zhang2">[35]</xref>, <xref ref-type="bibr" rid="pone.0099763-Pagaki1">[38]</xref>–<xref ref-type="bibr" rid="pone.0099763-Zhao2">[41]</xref>, grade of differentiation <xref ref-type="bibr" rid="pone.0099763-Kase1">[14]</xref>–<xref ref-type="bibr" rid="pone.0099763-Tamura1">[20]</xref>, <xref ref-type="bibr" rid="pone.0099763-Yamashita1">[25]</xref>, <xref ref-type="bibr" rid="pone.0099763-Shiwu1">[31]</xref>, <xref ref-type="bibr" rid="pone.0099763-Zhang2">[35]</xref>, <xref ref-type="bibr" rid="pone.0099763-Lim1">[37]</xref>–<xref ref-type="bibr" rid="pone.0099763-Jin1">[39]</xref>, tumor size <xref ref-type="bibr" rid="pone.0099763-Kase1">[14]</xref>, <xref ref-type="bibr" rid="pone.0099763-Kimura1">[15]</xref>, <xref ref-type="bibr" rid="pone.0099763-Hirata1">[17]</xref>, <xref ref-type="bibr" rid="pone.0099763-Huang1">[19]</xref>, <xref ref-type="bibr" rid="pone.0099763-Zhang2">[35]</xref>, <xref ref-type="bibr" rid="pone.0099763-Pagaki1">[38]</xref>, lymph node metastasis <xref ref-type="bibr" rid="pone.0099763-Kase1">[14]</xref>–<xref ref-type="bibr" rid="pone.0099763-Hirata1">[17]</xref>, <xref ref-type="bibr" rid="pone.0099763-Huang1">[19]</xref>, <xref ref-type="bibr" rid="pone.0099763-Yu1">[29]</xref>, <xref ref-type="bibr" rid="pone.0099763-Shiwu1">[31]</xref>, <xref ref-type="bibr" rid="pone.0099763-Zhang2">[35]</xref>, <xref ref-type="bibr" rid="pone.0099763-Pagaki1">[38]</xref>, <xref ref-type="bibr" rid="pone.0099763-Zhao2">[41]</xref>, pleural invasion <xref ref-type="bibr" rid="pone.0099763-Lee1">[16]</xref>, <xref ref-type="bibr" rid="pone.0099763-Lin1">[26]</xref>, <xref ref-type="bibr" rid="pone.0099763-Pagaki1">[38]</xref>, vascular invasion <xref ref-type="bibr" rid="pone.0099763-Kase1">[14]</xref>, <xref ref-type="bibr" rid="pone.0099763-Lee1">[16]</xref>, and TNM stages <xref ref-type="bibr" rid="pone.0099763-Lee1">[16]</xref>, <xref ref-type="bibr" rid="pone.0099763-Hirata1">[17]</xref>, <xref ref-type="bibr" rid="pone.0099763-Huang1">[19]</xref>, <xref ref-type="bibr" rid="pone.0099763-Tamura1">[20]</xref>, <xref ref-type="bibr" rid="pone.0099763-Yu1">[29]</xref>, <xref ref-type="bibr" rid="pone.0099763-Shiwu1">[31]</xref>, <xref ref-type="bibr" rid="pone.0099763-Kim1">[33]</xref>, <xref ref-type="bibr" rid="pone.0099763-Zhang2">[35]</xref>, <xref ref-type="bibr" rid="pone.0099763-Pagaki1">[38]</xref>–<xref ref-type="bibr" rid="pone.0099763-Zhao2">[41]</xref>. As showed in <xref ref-type="table" rid="pone-0099763-t002">Table 2</xref>, our analysis suggested that downregulation of E-cadherin was significantly associated with grade of differentiation (moderate/poor vs: well: OR = 1.71, 95% CI = 1.15–2.53, <italic>p</italic> = 0.008, I<sup>2</sup> = 68.6%, P&lt;0.001), lymphnode metastasis (yes vs no: OR = 2.07, 95% CI = 1.42–3.02, <italic>p</italic> = 0.001, I<sup>2</sup> = 71.8%, P&lt;0.001), vascular invasion (yes vs no: OR = 2.86, 95% CI = 1.43–5.73, <italic>p</italic> = 0.003, I<sup>2</sup> = 0.0%, P = 0.755), and TNM stages (III/IV vs. I/II: OR = 1.87, 95% CI = 1.27–2.76, <italic>p</italic> = 0.002, I<sup>2</sup> = 64.2%, P = 0.001). However, no significant association between downregulation of E-cadherin and histological type, tumor size, and pleural invasion was found (<xref ref-type="table" rid="pone-0099763-t002">Table 2</xref>).</p>
</sec><sec id="s3f">
<title>Publication bias</title>
<p>Begg's funnel plot and Egger's test were performed to assess the publication bias of studies. As showed in <xref ref-type="table" rid="pone-0099763-t002">Table 2</xref>, no publication bias was detected in all comparisons. The shape of the funnel plot was symmetrical for the all comparisons, <xref ref-type="fig" rid="pone-0099763-g005">Figure 5</xref> showed the funnel plot in the comparison of OS in patients with NSCLC.</p>
<fig id="pone-0099763-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0099763.g005</object-id><label>Figure 5</label><caption>
<title>The funnel plot of the meta-analysis of the impact of E-cadherin expression on overall survival (OS) in patients with NSCLC.</title>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0099763.g005" position="float" xlink:type="simple"/></fig></sec></sec><sec id="s4">
<title>Discussion</title>
<p>In this meta-analysis, we explored the prognostic role of E-cadherin expression in patients with NSCLC. Our analysis suggested that downregulation of E-cadherin was associated with poor OS and DFS/PFS in patients with NSCLC. When stage I NSCLC was separately analyzed, the prognostic impact on OS of downregulated E-cadherin was still significant. In addition, significant correlation was observed between E-cadherin expression and clinicopathological features including grade of differentiation, lymph node metastasis, vascular invasion, and TNM stages.</p>
<p>What are the possible mechanisms of E-cadherin in tumor progression? First, the loss of E-cadherin disrupts adhesion junctions between neighbouring cells and as a result, malignant cells detach from the epithelial-cell layer <xref ref-type="bibr" rid="pone.0099763-Christofori1">[42]</xref>. Second, loss of E-cadherin has direct effects on signalling pathways involved in tumour-cell migration and tumour growth, including the canonical Wnt signalling pathway and Rho family GTPase-mediated modulation of the actin cytoskeleton <xref ref-type="bibr" rid="pone.0099763-Sahai1">[43]</xref>, <xref ref-type="bibr" rid="pone.0099763-Vincan1">[44]</xref>. In addition, loss of E-cadherin expression is an epithelial-mesenchymal transition (EMT) hallmark <xref ref-type="bibr" rid="pone.0099763-Ye1">[45]</xref>, which participates in the progression and metastases of many epithelial tumors <xref ref-type="bibr" rid="pone.0099763-Arias1">[46]</xref>. the loss of E-cadherin is frequently correlated with the gain of expression of mesenchymal cadherins, such as N-cadherin, which enhance tumour-cell motility and migration <xref ref-type="bibr" rid="pone.0099763-Cavallaro1">[47]</xref>. Hence, the loss of E-cadherin may play a critical role in tumour invasion and metastatic dissemination, not only by changing the adhesive repertoire of a tumour cell, but also by modulating various signalling pathways and transcriptional responses <xref ref-type="bibr" rid="pone.0099763-Christofori1">[42]</xref>.</p>
<p>A previous meta-analysis by Wu et al. <xref ref-type="bibr" rid="pone.0099763-Wu1">[48]</xref> had been performed to examine the prognostic role in patients with NSCLC, and the result was consisted with us. However, our study showed the following advancements when compared with previous work. Firstly, our study included larger sample size than previous one. Wu closed their search time on 2011; however, after their work published, additional eight studies including 926 patients were published <xref ref-type="bibr" rid="pone.0099763-Yu1">[29]</xref>–<xref ref-type="bibr" rid="pone.0099763-Zhao1">[36]</xref>. These additional eight studies were included in our analysis, in some degree, our result was more robust and reliable than previous work. Secondly, our study showed lower heterogeneity than Wu's study in the investigation of the impact of E-cadherin expression on OS (34.8% vs 64%). Maybe more studies with larger sample size reduced the heterogeneity. Thirdly, In Wu's study, they did not found the significant association between E-cadherin and OS in stage I NSCLC patients; however, we found this significant association. They may ignore one study by Zhu et al. that they used receiver operating characteristic (ROC) curve analysis to determine the cutoff cutoff score of E-cadherin <xref ref-type="bibr" rid="pone.0099763-Zhu1">[23]</xref>. Beside, various subgroup analyses were done in our analysis, while in previous study, they only conducted subgroup analysis by race. At last, our study provided more information and gave a comprehensive insight on the role of E-cadherin in the progression of NSCLC. In Wu's study, they only investigated the relationship between E-cadherin expression and OS. However, in our study, we provided the information not only OS, but also DFS/PFS and clinicopathological features. The present study indicated downregulation of E-cadherin was significantly correlated with poor OS and DFS/PFS, additionally, downregulation of E-cadherin was associated with invasive phenotype (including grade of differentiation, lymph node metastasis, vascular invasion, and TNM stages) in NSCLC. Based on the above points, we thought our up-to date meta-analysis was worthwhile and comprehensive.</p>
<p>Various subgroup analyses were done. When we limited to the race, HR estimate, sample size, percentage of reduced/negative E-cadherin, and histological type, all these subgroups suggested the significant association between E-cadherin expression and poor OS. In addition, when we focus to stage I NSCLC, downregulated E-cadherin expression was associated with survival, suggesting this prognostic factor could also be of importance in early-stage NSCLC. What's more, E-cadherin expression was also related to poor DFS/PFS. In additional, downregulated E-cadherin expression was correlated with poor grade of differentiation, positive lymph node metastasis, positive vascular invasion, and advanced TNM stages, indicating downregulated E-cadherin in NSCLC presented invasive phenotypes. As a result, poor survival is very likely the consequence. All these evidence we observed demonstrated that E-cadherin was closely related to progression of NSCLC.</p>
<p>Our analysis provided the evidence that E-cadherin maybe a prognostic factor in NSCLC patients. However, as neoplastic progression is a complex and multiple-step process, E-cadherin may only play a small role. Combining E-cadherin with other biomarkers would be more meaningful and efficient, Also, gene-gene and gene-environment interaction showed be taken into consideration. Beside, E-cadherin may serve as a novel target and the application of individualized management in NSCLC patients. As loss of E-cadherin expression may associate with neoplastic progression, reconstitution of E-cadherin expression maybe an apparent attractive approach for treatment of NSCLC. This would be possible to prevent E-cadherin promoter methylation in some cases <xref ref-type="bibr" rid="pone.0099763-Paredes1">[5]</xref>. In addition, the signalling pathways such as such as HER receptors (HER2/neu and EGFR) and Notch downstream targets are aberrantly activated in consequence of E-cadherin loss. Since EGFR and Notch inhibitors are already developed as therapeutic agents in diverse tumour models, these targets and associated pathways will create the basis for the development of new therapeutic control in E-cadherin-mediated cancer <xref ref-type="bibr" rid="pone.0099763-Paredes1">[5]</xref>.</p>
<p>Some limitations should be acknowledged.</p>
<p>Firstly, in the studies we included, IHC techniques used to detect protein expression were not the same (including antibody type and concentration, the cutoff value definition). These differences could contribute to the heterogeneity.</p>
<p>Secondly, postoperative adjuvant therapy should be taken into consideration. The included studies showed the different management. Some only received surgery, while others received additional adjuvant chemotherapy and (or) adjuvant radiotherapy. This may be one of the major resources of heterogeneity.</p>
<p>Moreover, the HRs and their 95% CI we extracted from the OS data were not consistent. We have to estimate the HRs by reading the Kaplan-Meier curves because some studies did not report the HRs. Some studies reported the unadjusted HRs while the others provided the adjusted HRs. Moreover, the cofounders they adjusted were not the same for the adjusted HRs. All of these factors more or less contributed to the heterogeneity.</p>
<p>At last, potential publication biases may exist. Articles were not written in English and studies failed to get published because of negative or null results cannot be identified in our literature search and thus were not included in this analysis. In addition, some reports did not provide sufficient data were also excluded from our analysis.</p>
<p>In conclusion, our study indicated that downregulated E-cadherin expression correlate with tumour progression and prognosis of NSCLC patients. E-cadherin might be a predicative factor of progression, and prognosis of patients with NSCLC. With the limitations, heterogeneities, and bias of meta-analysis, our conclusions in this study need to be interpreted with caution. Future large prospective studies with rigorously designed methodology are warranted to confirm our results.</p>
</sec><sec id="s5">
<title>Supporting Information</title>
<supplementary-material id="pone.0099763.s001" mimetype="application/msword" xlink:href="info:doi/10.1371/journal.pone.0099763.s001" position="float" xlink:type="simple"><label>Figure S1</label><caption>
<p>PRISMA Flow Diagram.</p>
<p>(DOC)</p>
</caption></supplementary-material><supplementary-material id="pone.0099763.s002" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" xlink:href="info:doi/10.1371/journal.pone.0099763.s002" position="float" xlink:type="simple"><label>Table S1</label><caption>
<p>Quality assessment of eligible studies with Newcastle-Ottawa Scale.</p>
<p>(DOCX)</p>
</caption></supplementary-material><supplementary-material id="pone.0099763.s003" mimetype="application/msword" xlink:href="info:doi/10.1371/journal.pone.0099763.s003" position="float" xlink:type="simple"><label>Checklist S1</label><caption>
<p>PRISMA Checklist.</p>
<p>(DOC)</p>
</caption></supplementary-material></sec></body>
<back><ref-list>
<title>References</title>
<ref id="pone.0099763-International1"><label>1</label>
<mixed-citation publication-type="other" xlink:type="simple">International Agency for Research on Cancer, W.H.O (2012) GLOBOCAN 2012:Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Available: <ext-link ext-link-type="uri" xlink:href="http://globocaniarcfr(accessed" xlink:type="simple">http://globocaniarcfr(accessed</ext-link> 2014 Jan 12).</mixed-citation>
</ref>
<ref id="pone.0099763-Govindan1"><label>2</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Govindan</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Page</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Morgensztern</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Read</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Tierney</surname><given-names>R</given-names></name>, <etal>et al</etal>. (<year>2006</year>) <article-title>Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database</article-title>. <source>J Clin Oncol</source> <volume>24</volume>: <fpage>4539</fpage>–<lpage>4544</lpage>.</mixed-citation>
</ref>
<ref id="pone.0099763-Morgensztern1"><label>3</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Morgensztern</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Ng</surname><given-names>SH</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Govindan</surname><given-names>R</given-names></name> (<year>2010</year>) <article-title>Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey</article-title>. <source>J Thorac Oncol</source> <volume>5</volume>: <fpage>29</fpage>–<lpage>33</lpage>.</mixed-citation>
</ref>
<ref id="pone.0099763-Chansky1"><label>4</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chansky</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Sculier</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Crowley</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Giroux</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Van Meerbeeck</surname><given-names>J</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer</article-title>. <source>J Thorac Oncol</source> <volume>4</volume>: <fpage>792</fpage>–<lpage>801</lpage>.</mixed-citation>
</ref>
<ref id="pone.0099763-Paredes1"><label>5</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Paredes</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Figueiredo</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Albergaria</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Oliveira</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Carvalho</surname><given-names>J</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Epithelial E- and P-cadherins: role and clinical significance in cancer</article-title>. <source>Biochim Biophys Acta</source> <volume>1826</volume>: <fpage>297</fpage>–<lpage>311</lpage>.</mixed-citation>
</ref>
<ref id="pone.0099763-Birchmeier1"><label>6</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Birchmeier</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Behrens</surname><given-names>J</given-names></name> (<year>1994</year>) <article-title>Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness</article-title>. <source>Biochim Biophys Acta</source> <volume>1198</volume>: <fpage>11</fpage>–<lpage>26</lpage>.</mixed-citation>
</ref>
<ref id="pone.0099763-Wells1"><label>7</label>
<mixed-citation publication-type="other" xlink:type="simple">Wells GA, Shea B, O'Connell D, Peterson J, Welch V, <etal>et al</etal>.. (2003) The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: <ext-link ext-link-type="uri" xlink:href="http://wwwohrica/programs/clinicalepidemiology/oxfordasp(accessed" xlink:type="simple">http://wwwohrica/programs/clinicalepidemiology/oxfordasp(accessed</ext-link> 2013 Oct 12)</mixed-citation>
</ref>
<ref id="pone.0099763-Tierney1"><label>8</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tierney</surname><given-names>JF</given-names></name>, <name name-style="western"><surname>Stewart</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Ghersi</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Burdett</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Sydes</surname><given-names>MR</given-names></name> (<year>2007</year>) <article-title>Practical methods for incorporating summary time-to-event data into meta-analysis</article-title>. <source>Trials</source> <volume>8</volume>: <fpage>16</fpage>.</mixed-citation>
</ref>
<ref id="pone.0099763-Higgins1"><label>9</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Higgins</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Thompson</surname><given-names>SG</given-names></name>, <name name-style="western"><surname>Deeks</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Altman</surname><given-names>DG</given-names></name> (<year>2003</year>) <article-title>Measuring inconsistency in meta-analyses</article-title>. <source>BMJ</source> <volume>327</volume>: <fpage>557</fpage>–<lpage>560</lpage>.</mixed-citation>
</ref>
<ref id="pone.0099763-Mantel1"><label>10</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mantel</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Haenszel</surname><given-names>W</given-names></name> (<year>1959</year>) <article-title>Statistical aspects of the analysis of data from retrospective studies of disease</article-title>. <source>J Natl Cancer Inst</source> <volume>22</volume>: <fpage>719</fpage>–<lpage>748</lpage>.</mixed-citation>
</ref>
<ref id="pone.0099763-DerSimonian1"><label>11</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>DerSimonian</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Laird</surname><given-names>N</given-names></name> (<year>1986</year>) <article-title>Meta-analysis in clinical trials</article-title>. <source>Control Clin Trials</source> <volume>7</volume>: <fpage>177</fpage>–<lpage>188</lpage>.</mixed-citation>
</ref>
<ref id="pone.0099763-Begg1"><label>12</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Begg</surname><given-names>CB</given-names></name>, <name name-style="western"><surname>Mazumdar</surname><given-names>M</given-names></name> (<year>1994</year>) <article-title>Operating characteristics of a rank correlation test for publication bias</article-title>. <source>Biometrics</source> <volume>50</volume>: <fpage>1088</fpage>–<lpage>1101</lpage>.</mixed-citation>
</ref>
<ref id="pone.0099763-Egger1"><label>13</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Egger</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Davey Smith</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Schneider</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Minder</surname><given-names>C</given-names></name> (<year>1997</year>) <article-title>Bias in meta-analysis detected by a simple, graphical test</article-title>. <source>BMJ</source> <volume>315</volume>: <fpage>629</fpage>–<lpage>634</lpage>.</mixed-citation>
</ref>
<ref id="pone.0099763-Kase1"><label>14</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kase</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Sugio</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Yamazaki</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Okamoto</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Yano</surname><given-names>T</given-names></name>, <etal>et al</etal>. (<year>2000</year>) <article-title>Expression of E-cadherin and beta-catenin in human non-small cell lung cancer and the clinical significance</article-title>. <source>Clin Cancer Res</source> <volume>6</volume>: <fpage>4789</fpage>–<lpage>4796</lpage>.</mixed-citation>
</ref>
<ref id="pone.0099763-Kimura1"><label>15</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kimura</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Endo</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Yonemura</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Heizmann</surname><given-names>CW</given-names></name>, <name name-style="western"><surname>Schafer</surname><given-names>BW</given-names></name>, <etal>et al</etal>. (<year>2000</year>) <article-title>Clinical significance of S100A4 and E-cadherin-related adhesion molecules in non-small cell lung cancer</article-title>. <source>Int J Oncol</source> <volume>16</volume>: <fpage>1125</fpage>–<lpage>1131</lpage>.</mixed-citation>
</ref>
<ref id="pone.0099763-Lee1"><label>16</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lee</surname><given-names>YC</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>CT</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>CS</given-names></name>, <name name-style="western"><surname>Chang</surname><given-names>YL</given-names></name> (<year>2000</year>) <article-title>E-cadherin expression in surgically-resected non-small cell lung cancers–a clinicopathological study</article-title>. <source>Thorac Cardiovasc Surg</source> <volume>48</volume>: <fpage>294</fpage>–<lpage>299</lpage>.</mixed-citation>
</ref>
<ref id="pone.0099763-Hirata1"><label>17</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hirata</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Fukuse</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Naiki</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Wada</surname><given-names>H</given-names></name> (<year>2001</year>) <article-title>Expression of E-cadherin and lymph node metastasis in resected non-small-cell lung cancer</article-title>. <source>Clin Lung Cancer</source> <volume>3</volume>: <fpage>134</fpage>–<lpage>140</lpage>.</mixed-citation>
</ref>
<ref id="pone.0099763-Deeb1"><label>18</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Deeb</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Ramnath</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Slocum</surname><given-names>HK</given-names></name>, <name name-style="western"><surname>Wiseman</surname><given-names>S</given-names></name>, <etal>et al</etal>. (<year>2004</year>) <article-title>Altered E-cadherin and epidermal growth factor receptor expressions are associated with patient survival in lung cancer: a study utilizing high-density tissue microarray and immunohistochemistry</article-title>. <source>Mod Pathol</source> <volume>17</volume>: <fpage>430</fpage>–<lpage>439</lpage>.</mixed-citation>
</ref>
<ref id="pone.0099763-Huang1"><label>19</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Huang</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Masuya</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Nakashima</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Kameyama</surname><given-names>K</given-names></name>, <etal>et al</etal>. (<year>2005</year>) <article-title>Clinical application of biological markers for treatments of resectable non-small-cell lung cancers</article-title>. <source>Br J Cancer</source> <volume>92</volume>: <fpage>1231</fpage>–<lpage>1239</lpage>.</mixed-citation>
</ref>
<ref id="pone.0099763-Tamura1"><label>20</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tamura</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ohta</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Tsunezuka</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Matsumoto</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Kawakami</surname><given-names>K</given-names></name>, <etal>et al</etal>. (<year>2005</year>) <article-title>Prognostic significance of dysadherin expression in patients with non-small cell lung cancer</article-title>. <source>J Thorac Cardiovasc Surg</source> <volume>130</volume>: <fpage>740</fpage>–<lpage>745</lpage>.</mixed-citation>
</ref>
<ref id="pone.0099763-AlSaad1"><label>21</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Al-Saad</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Al-Shibli</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Donnem</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Persson</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Bremnes</surname><given-names>RM</given-names></name>, <etal>et al</etal>. (<year>2008</year>) <article-title>The prognostic impact of NF-kappaB p105, vimentin, E-cadherin and Par6 expression in epithelial and stromal compartment in non-small-cell lung cancer</article-title>. <source>Br J Cancer</source> <volume>99</volume>: <fpage>1476</fpage>–<lpage>1483</lpage>.</mixed-citation>
</ref>
<ref id="pone.0099763-Cho1"><label>22</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cho</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Sung</surname><given-names>SW</given-names></name>, <name name-style="western"><surname>Jheon</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Chung</surname><given-names>JH</given-names></name> (<year>2008</year>) <article-title>Risk of recurrence in surgically resected stage I adenocarcinoma of the lung: histopathologic and immunohistochemical analysis</article-title>. <source>Lung</source> <volume>186</volume>: <fpage>411</fpage>–<lpage>419</lpage>.</mixed-citation>
</ref>
<ref id="pone.0099763-Zhu1"><label>23</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zhu</surname><given-names>ZH</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>BY</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Shao</surname><given-names>JY</given-names></name>, <name name-style="western"><surname>Long</surname><given-names>H</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Three immunomarker support vector machines-based prognostic classifiers for stage IB non-small-cell lung cancer</article-title>. <source>J Clin Oncol</source> <volume>27</volume>: <fpage>1091</fpage>–<lpage>1099</lpage>.</mixed-citation>
</ref>
<ref id="pone.0099763-Ono1"><label>24</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ono</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Uramoto</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Hanagiri</surname><given-names>T</given-names></name> (<year>2010</year>) <article-title>Expression of dysadherin and cytokeratin as prognostic indicators of disease-free survival in patients with stage I NSCLC</article-title>. <source>Anticancer Res</source> <volume>30</volume>: <fpage>3273</fpage>–<lpage>3278</lpage>.</mixed-citation>
</ref>
<ref id="pone.0099763-Yamashita1"><label>25</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yamashita</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Uramoto</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Onitsuka</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Ono</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Baba</surname><given-names>T</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Association between lymphangiogenesis-/micrometastasis- and adhesion-related molecules in resected stage I NSCLC</article-title>. <source>Lung Cancer</source> <volume>70</volume>: <fpage>320</fpage>–<lpage>328</lpage>.</mixed-citation>
</ref>
<ref id="pone.0099763-Lin1"><label>26</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lin</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Shen</surname><given-names>ZY</given-names></name>, <name name-style="western"><surname>Xiong</surname><given-names>LW</given-names></name>, <name name-style="western"><surname>Pan</surname><given-names>XF</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Prognostic impact of vascular endothelial growth factor-A and E-cadherin expression in completely resected pathologic stage I non-small cell lung cancer</article-title>. <source>Jpn J Clin Oncol</source> <volume>40</volume>: <fpage>670</fpage>–<lpage>676</lpage>.</mixed-citation>
</ref>
<ref id="pone.0099763-Sterlacci1"><label>27</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sterlacci</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Fiegl</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hilbe</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Jamnig</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Oberaigner</surname><given-names>W</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Deregulation of p27 and cyclin D1/D3 control over mitosis is associated with unfavorable prognosis in non-small cell lung cancer, as determined in 405 operated patients</article-title>. <source>J Thorac Oncol</source> <volume>5</volume>: <fpage>1325</fpage>–<lpage>1336</lpage>.</mixed-citation>
</ref>
<ref id="pone.0099763-Ucvet1"><label>28</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ucvet</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Kul</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Gursoy</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Erbaycu</surname><given-names>AE</given-names></name>, <name name-style="western"><surname>Kaya</surname><given-names>SO</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>[Prognostic value of epithelial growth factor receptor, vascular endothelial growth factor, E-cadherin, and p120 catenin in resected non-small cell lung carcinoma]</article-title>. <source>Arch Bronconeumol</source> <volume>47</volume>: <fpage>397</fpage>–<lpage>402</lpage>.</mixed-citation>
</ref>
<ref id="pone.0099763-Yu1"><label>29</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yu</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Shi</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Qiu</surname><given-names>X</given-names></name> (<year>2011</year>) <article-title>Expression of integrin-linked kinase in lung squamous cell carcinoma and adenocarcinoma: correlation with E-cadherin expression, tumor microvessel density and clinical outcome</article-title>. <source>Virchows Arch</source> <volume>458</volume>: <fpage>99</fpage>–<lpage>107</lpage>.</mixed-citation>
</ref>
<ref id="pone.0099763-Richardson1"><label>30</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Richardson</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Young</surname><given-names>GD</given-names></name>, <name name-style="western"><surname>Sennello</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Wolf</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Argast</surname><given-names>GM</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>The evaluation of E-Cadherin and vimentin as biomarkers of clinical outcomes among patients with non-small cell lung cancer treated with erlotinib as second- or third-line therapy</article-title>. <source>Anticancer Res</source> <volume>32</volume>: <fpage>537</fpage>–<lpage>552</lpage>.</mixed-citation>
</ref>
<ref id="pone.0099763-Shiwu1"><label>31</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shiwu</surname><given-names>WU</given-names></name>, <name name-style="western"><surname>Lan</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Wenqing</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Lei</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Yisheng</surname><given-names>T</given-names></name> (<year>2012</year>) <article-title>Expression and clinical significance of CD82/KAI1 and E-cadherin in non-small cell lung cancer</article-title>. <source>Arch Iran Med</source> <volume>15</volume>: <fpage>707</fpage>–<lpage>712</lpage>.</mixed-citation>
</ref>
<ref id="pone.0099763-Feng1"><label>32</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Feng</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Ni</surname><given-names>S</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>FoxQ1 overexpression influences poor prognosis in non-small cell lung cancer, associates with the phenomenon of EMT</article-title>. <source>PLoS One</source> <volume>7</volume>: <fpage>e39937</fpage>.</mixed-citation>
</ref>
<ref id="pone.0099763-Kim1"><label>33</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kim</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Yoo</surname><given-names>SB</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Jin</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Jheon</surname><given-names>S</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Alteration of the E-Cadherin/beta-Catenin Complex Is an Independent Poor Prognostic Factor in Lung Adenocarcinoma</article-title>. <source>Korean J Pathol</source> <volume>47</volume>: <fpage>44</fpage>–<lpage>51</lpage>.</mixed-citation>
</ref>
<ref id="pone.0099763-Zhang1"><label>34</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Kang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>X</given-names></name>, <etal>et al</etal>. (<year>2014</year>) <article-title>MCAM expression is associated with poor prognosis in non-small cell lung cancer</article-title>. <source>Clin Transl Oncol</source> <volume>16</volume>: <fpage>178</fpage>–<lpage>183</lpage>.</mixed-citation>
</ref>
<ref id="pone.0099763-Zhang2"><label>35</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Yue</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>D</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Clinical significance of E-cadherin, beta-catenin, vimentin and S100A4 expression in completely resected squamous cell lung carcinoma</article-title>. <source>J Clin Pathol</source> <volume>66</volume>: <fpage>937</fpage>–<lpage>945</lpage>.</mixed-citation>
</ref>
<ref id="pone.0099763-Zhao1"><label>36</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zhao</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Qin</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>QQ</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>YL</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>SCUBE3 overexpression predicts poor prognosis in non-small cell lung cancer</article-title>. <source>Biosci Trends</source> <volume>7</volume>: <fpage>264</fpage>–<lpage>269</lpage>.</mixed-citation>
</ref>
<ref id="pone.0099763-Lim1"><label>37</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lim</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Jang</surname><given-names>IG</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>YC</given-names></name>, <name name-style="western"><surname>Park</surname><given-names>KO</given-names></name> (<year>2000</year>) <article-title>The role of E-cadherin expression in non-small cell lung cancer</article-title>. <source>J Korean Med Sci</source> <volume>15</volume>: <fpage>501</fpage>–<lpage>506</lpage>.</mixed-citation>
</ref>
<ref id="pone.0099763-Pagaki1"><label>38</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pagaki</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Patsouris</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Gonidi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Athanassiadou</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Maurikakis</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>The value of E-cadherin/beta-catenin expression in imprints of NCSLC: relationship with clinicopathological factors</article-title>. <source>Diagn Cytopathol</source> <volume>38</volume>: <fpage>419</fpage>–<lpage>424</lpage>.</mixed-citation>
</ref>
<ref id="pone.0099763-Jin1"><label>39</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jin</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Shi</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>R</given-names></name> (<year>2012</year>) <article-title>Clinicopathological significance of lymphatic vessel density marked by D2-40 and E-cadherin expression in non-small-cell lung cancer</article-title>. <source>Med Oncol</source> <volume>29</volume>: <fpage>3157</fpage>–<lpage>3161</lpage>.</mixed-citation>
</ref>
<ref id="pone.0099763-Shi1"><label>40</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shi</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ding</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Meng</surname><given-names>F</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Expression of the epithelial-mesenchymal transition-related proteins and their clinical significance in lung adenocarcinoma</article-title>. <source>Diagn Pathol</source> <volume>8</volume>: <fpage>89</fpage>.</mixed-citation>
</ref>
<ref id="pone.0099763-Zhao2"><label>41</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zhao</surname><given-names>JQ</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>FJ</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>SS</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>YQ</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Expression of connexin 43 and E-cadherin protein and mRNA in non-small cell lung cancers in Chinese patients</article-title>. <source>Asian Pac J Cancer Prev</source> <volume>14</volume>: <fpage>639</fpage>–<lpage>643</lpage>.</mixed-citation>
</ref>
<ref id="pone.0099763-Christofori1"><label>42</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Christofori</surname><given-names>G</given-names></name> (<year>2006</year>) <article-title>New signals from the invasive front</article-title>. <source>Nature</source> <volume>441</volume>: <fpage>444</fpage>–<lpage>450</lpage>.</mixed-citation>
</ref>
<ref id="pone.0099763-Sahai1"><label>43</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sahai</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Marshall</surname><given-names>CJ</given-names></name> (<year>2002</year>) <article-title>RHO-GTPases and cancer</article-title>. <source>Nat Rev Cancer</source> <volume>2</volume>: <fpage>133</fpage>–<lpage>142</lpage>.</mixed-citation>
</ref>
<ref id="pone.0099763-Vincan1"><label>44</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Vincan</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Barker</surname><given-names>N</given-names></name> (<year>2008</year>) <article-title>The upstream components of the Wnt signalling pathway in the dynamic EMT and MET associated with colorectal cancer progression</article-title>. <source>Clin Exp Metastasis</source> <volume>25</volume>: <fpage>657</fpage>–<lpage>663</lpage>.</mixed-citation>
</ref>
<ref id="pone.0099763-Ye1"><label>45</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ye</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Shen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Ni</surname><given-names>C</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Enrichment of colorectal cancer stem cells through epithelial-mesenchymal transition via CDH1 knockdown</article-title>. <source>Mol Med Rep</source> <volume>6</volume>: <fpage>507</fpage>–<lpage>512</lpage>.</mixed-citation>
</ref>
<ref id="pone.0099763-Arias1"><label>46</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Arias</surname><given-names>AM</given-names></name> (<year>2001</year>) <article-title>Epithelial mesenchymal interactions in cancer and development</article-title>. <source>Cell</source> <volume>105</volume>: <fpage>425</fpage>–<lpage>431</lpage>.</mixed-citation>
</ref>
<ref id="pone.0099763-Cavallaro1"><label>47</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cavallaro</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Christofori</surname><given-names>G</given-names></name> (<year>2004</year>) <article-title>Cell adhesion and signalling by cadherins and Ig-CAMs in cancer</article-title>. <source>Nat Rev Cancer</source> <volume>4</volume>: <fpage>118</fpage>–<lpage>132</lpage>.</mixed-citation>
</ref>
<ref id="pone.0099763-Wu1"><label>48</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>HB</given-names></name>, <name name-style="western"><surname>Ding</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>JN</given-names></name>, <name name-style="western"><surname>Zhan</surname><given-names>P</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>The impact of E-cadherin expression on non-small cell lung cancer survival: a meta-analysis</article-title>. <source>Mol Biol Rep</source> <volume>39</volume>: <fpage>9621</fpage>–<lpage>9628</lpage>.</mixed-citation>
</ref>
</ref-list></back>
</article>